Csenge Advisory Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Csenge Advisory Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$507K	Buy	+2,683	New	+$469K	0.02%	429
2020 Q1	–	Sell	-1,378	Closed	-$206K	–	321
2019 Q4	$206K	Buy	+1,378	New	+$188K	0.05%	276
2019 Q3	–	Sell	-1,506	Closed	-$214K	–	279
2019 Q2	$214K	Sell	1,506 -91	-6%	-$12.2K	0.07%	174
2019 Q1	$228K	Buy	+1,597	New	+$208K	0.08%	179

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Csenge Advisory Group's JAZZ Position: Q1 2026 in Review

Csenge Advisory Group opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 2,683 shares worth $507K. The stake represents 0.02% of the portfolio and ranks #429 among its holdings. This is a return to the name: Csenge Advisory Group previously reported a position in JAZZ as recently as Q4 2019.

Csenge Advisory Group first reported a position in JAZZ in Q1 2019 and has held it in 4 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Csenge Advisory Group held 2,683 shares of Jazz Pharmaceuticals worth $507K as of Q1 2026.
Jazz Pharmaceuticals was a new Csenge Advisory Group position in Q1 2026.
Jazz Pharmaceuticals made up 0.02% of Csenge Advisory Group's portfolio in Q1 2026, its #429 holding.
Csenge Advisory Group first reported a position in Jazz Pharmaceuticals in Q1 2019 and has held it in 4 quarters since.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Csenge Advisory Group's 13F filing for Q1 2026, filed 30 Apr 2026.